Nuestros recursos

Listen in as industry leaders discuss how to execute successful DCTs by building a seamless patient experience from enrollment to trial completion.

One of the keys to optimizing ePRO is deploying artificial intelligence (AI) to support human participants and clinical teams.

The unique challenges associated with women’s health, and women as a cohort, make clinical research in this sector especially difficult. DCTs are helping to tackle the obstacles.

eConsent can mitigate these shortcomings by providing flexibility and engagement that empower patients with information and sponsors with data integrity.

Diversity in clinical trials is a scientific imperative, a moral and ethical necessity—and a longstanding challenge in clinical research. DCTs are evolving the industry status quo.

ObvioHealth, a leading global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trial solutions, announces the development of two novel digital instruments to increase accuracy and reduce patient/caregiver burden in pediatric clinical trials.

ObvioHealth and 1nHealth announce today a joint initiative to smooth the transition to hybrid and decentralized clinical research. The initiative focuses on supporting clinical trials that may be struggling due to suboptimal protocol design, imprecise recruitment strategies, maladapted technology options or ailing site teams. According to clinicaltrials.gov, there are about 1,600 suspended trials at present.

How do increasingly prevalent DCT methods fit into the existing clinical trial ecosystem? In short: There are complexities. Many eClinical platforms still lack key capabilities, which often require complex integrations with third-party solutions.